Motilal Oswal's research report on LIC Housing Finance
Our strategist recently increased the weightage of LIC Housing Finance (LICHF) in our model portfolio. In our view, after a span of two years, the business environment is turning favorable for LICHF. With liquidity tightening,
Banking and financial services stocks have been key drivers of the current rally that has led benchmark indices to fresh six-month highs. The up move has been fuelled by hopes of Modi's return at the Centre and renewed FII inflow.
Bank Nifty has rallied 10 percent in March so far and f
The maze of government rules can create unexpected outcomes. And that’s certainly the case for 2018 Medicare premiums. While the standard Part B premium remains $134 a month, many beneficiaries will pay more for Part B. The culprit in this counterintuitive result? The hold-harmless provision.
SEE ALSO: Special Report: Navigating Medicare
Last year, this provision had a positive....More>>>
Kirkland Lake Gold (NYSE: KL) and Osisko Gold Royalties (NYSE:OR) are both basic materials companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, profitability, institutional ownership and earnings.
Tencent (NASDAQOTH:TCEHY) recently announced that it will invest about $318 million in Bilibili (NASDAQ:BILI) by buying 25 million newly issued Class Z shares at $12.67 per share. The investment will give Tencent a 12% stake in the Chinese tech company, which went public in March.
This move might seem like another scattershot investment for Tencent, which owns stakes in a wide range of....More>>>
Argent Trust Co increased its stake in shares of Philip Morris International Inc. (NYSE:PM) by 121.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,602 shares of the company’s stock after buying an additional 9,643 shares during the quarter. Argent Trust Co’s holdings in....More>>>
Facebook’s (NASDAQ:FB) billion-dollar acquisition of Instagram in 2012 seemed utterly insane at the time. The photo/video sharing service had just a handful of employees back then and less than 30 million registered users. In the years since, Facebook has executed incredibly well with growing Instagram, which is well on its way to becoming Facebook’s fourth billion-user platform, alongside....More>>>
More than seven in 10 Americans who watched President Trump's speech on Tuesday night came away with a positive reaction, according to a CNN poll… And 57% of viewers had a very positive reaction. While it wasn't technically a State of the Union speech, CNN notes this is the most positive reaction to a U.S. president's address to Congress since Barack Obama's first....More>>>
On Thursday, our Under the Radar Moversnewsletter suggested small cap manufacturing and 3D printing service provider ARC Group WorldWide (NASDAQ: ARCW) as a short trade:
The shape of today’s bar has a lot to do with our bearish thesis, though circumstances mean a lot too. The shape is a tall bar with an open and a close (so far) near the low for the day. This says the buyers tried to....More>>>
Are marijuana and hemp the same thing? It largely depends who you ask. The federal government accurately recognizes that hemp and marijuana are variants of the same species…. Cannabis sativa, but aren’t one and the same. Yet, the DEA recently put rules in place that suggest they’re not going to act as if no distinction exists (though that matter is still not clarified by legislative....More>>>
La Jolla Pharmaceutical (LJPC) recently announced that it had entered into a financing deal that would help it with the launch of its drug Giapreza. This not only helps the biotech with the commercial launch of the drug, but it also provides cash to fund other products in the pipeline like LJPC-401. That’s why I believe it is a good buy after this funding announcement.
The most expensive stocks often receive a disproportionate share of the coverage in the financial news industry. Since those stocks often emerge from cutting-edge industries, they tend to win investor attention as they often represent the future.
Amgen (NASDAQ:AMGN) and Biogen (NASDAQ:BIIB) have a lot in common. They are both hugely successful biotech giants that were founded decades ago. They each have produced stellar returns for their long-term shareholders and crank out copious amounts of cash flow each year.
Celgene (CELG) has three key drugs in its late-stage pipeline and yet the market refuses to buy the stock. Bearishness is building up so much that the stock fell sharply on May 21. This continues the downtrend that began last year in Sept. 2017, when the stock traded at over $140 a share. The c
This has been a bad year for Biogen (NASDAQ:BIIB) so far -- the biotech's stock has dropped more than 10% since it began. But 2018 has been horrible for Acadia Pharmaceuticals (NASDAQ:ACAD), which has seen its share price plunge nearly 40%.